• 

• PROVEN EFFICACY ^2,3,4 62% responder rate in PHN, comparable to systemic treatment³...

  • Versatis^® shows a 62% responder rate in PHN, comparable to systemic treatment ³

    

    

    Per protocol set (PPS). Response was defined as ≥2 point reduction in baseline NRS-3 score or overall score ≤4. Adapted from Baron et al. (2009).

  • More than 80% of responding Versatis^® PHN patients experienced pain relief within the first two weeks ²

    

    

    Of patients showing pain relief at week 4, 82.1% (23/28) of those using Versatis^® had already responded at week 2, compared to 65% (13/20) with pregabalin²

    To monitor the effectiveness of Versatis^®, it is recommended to re-evaluate the treatment outcome after 2-4 weeks.¹

     

    Response defined as a reduction averaged over the last 3 days from baseline of >2 points or an absolute value <4 points on the NRS-3 scale (patients’ recalled average pain intensity over the last 3 days measured on an 11-point rating scale from 0 = no pain to 10 = worst pain imaginable.

  • Up to 4 years’ clinical data confirms sustained long-term effect of Versatis^® in PHN patients⁴

    

    

    Adapted from Sabatowski R et al. Safety and Efficacy Outcomes of Long-term Treatment up to 4 Years with 5% Lidocaine Medicated Plaster in Patients with Post-Herpetic Neuralgia.

    Hear Professor Gunnar Wasner’s thoughts on Versatis:

    "The 5% lidocaine medicated plaster has a proven long-term efficacy in neuropathic pain associated with post-herpetic neuralgia (PHN)."

    Professor Gunnar Wasner
    (Dept. of Neurology, Division of Neurological Pain Research and Therapy, Kiel)

     

• SUPERIOR TOLERABILITY ^1,3,+Low systemic side effects...

  • As a targeted topical treatment for PHN patients, Versatis demonstrates low systemic side effects¹

    "...there are benefits for a local, topical therapy, rather than using a systemic drug with a not as favourable side effect profile."

    Dr Winston De Mello
    (Consultant in Anaesthesia and Pain Medicine at the University Hospital of South Manchester, UK)

    Hear Dr De Mello's views on the use of local treatment for PHN:

    "...a localised disease needs a localised treatment."

    Dr Winston De Mello
    (Consultant in Anaesthesia and Pain Medicine at the University Hospital of South Manchester, UK)

    (+Compared to pregabalin)

  • Versatis is well tolerated; with less than 5% treatment discontinuation due to adverse drug reactions in PHN patients ¹

    

    

    
     

    Find out about the science behind Versatis^®.

• EASY TO USE ^1,7No titration necessary...

  As a targeted topical treatment for PHN patients, Versatis^® works where it hurts.

  Patients can simply apply a Versatis^® plaster directly to the area of pain

  Versatis^® does not need to be titrated ¹

  Larger areas can be covered with up to three Versatis^® plasters at the same time ¹

  Discover the 3 easy steps to relief from post-shingles pain (PHN) with Versatis^®.

  Preparation

  

  Versatis^® works where it hurts¹ - identify the most painful areas of PHN (post-herpetic neuralgia) pain.

  Apply the plaster only on dry and intact skin.

  Handling

  

  Tear open or cut the envelope along the dotted line.

  Versatis^® plaster plaster may be cut to size.

  Reseal the package by using the seal. The adhesive contains water and will dry out if the package is left open.

  Remove the clear plastic backing from the plaster and apply it to the area of pain.

  Application

  

  Use up to 3 Versatis^® plasters to cover the most painful area. ¹

  12 hours on, 12 hours off. ¹

  Versatis^® can be worn for up to 12 hours, followed by 12 hours off before another Versatis^® plaster can be applied. ¹

  See how simple it is to incorporate Versatis^® into everyday life:

GrunenthalPharma Ltd, 4045 Kingswood Road, Citywest Business Park, Citywest, Co. Dublin. Email: generalenquiriesIE@grunenthal.com.
Phone: +44 (0) 870 351 8960, Fax: + 353 (0) 1 466 0793